All News

Surbhi Sidana, MD, discusses how CELMoDs like iberdomide could complement CAR T and bispecific antibody therapies.

The FRα-directed ADC rinatabart sesutecan showed disease control regardless of biomarker status and is now under investigation in the phase 3 RAINFOL-03 trial.

Ayal Aizer, MD, MHS, describes an adaptive planning trial using synthetic CT to improve same-day treatment accuracy for anatomically unstable brain metastases.

Oncology experts discussed the wide-ranging benefits of exercise in oncology care, including enhanced treatment efficacy, minimal AEs, and minimal expenses.

The FDA has approved daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma based on RASolute 302 trial data.

In a real-world setting, venetoclax plus a hypomethylating agent produced a median overall survival of 13.0 months in newly diagnosed acute myeloid leukemia.

The availability of iberdomide as an easy-to-give, orally available drug “is tremendous” for patients with multiple myeloma, according to Surbhi Sidana, MD.

Experts discussed the rapidly expanding radiopharmaceutical paradigm and how to integrate such technology into real-world oncology practice.

Lizza Hendriks, MD, PhD, discussed why every patient with CNS metastases deserves a multidisciplinary team discussion.

The FDA granted fast track designation to the pan-RAS molecular glue ERAS-0015 for metastatic pancreatic adenocarcinoma.

Starting lenvatinib at 14 mg instead of the trial’s 20-mg dose helps patients remain on therapy, according to Susana Campos, MD, MPH.

In a real-world setting, enfortumab vedotin plus pembrolizumab produced a 50.2% ORR among patients with metastatic/locally advanced urothelial carcinoma.

The FDA has approved zanidatamab plus chemotherapy for the first-line treatment of HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma.

Japan’s MHLW approved sevabertinib for HER2-mutant advanced or recurrent NSCLC across all lines of therapy based on phase 1/2 SOHO-01 data.

Lizza Hendriks, MD, PhD, discusses clinical trial designs, multidisciplinary care, and promising research at the 2026 SNO ASCO CNS Metastases Conference.

Ayal Aizer, MD, MHS, discusses radiation necrosis as the next major challenge in stereotactic radiosurgery for brain metastases and how clinicians can address it.

Because it is not biomarker directed, lenvatinib plus pembrolizumab remains broadly useful even as HER2-targeted ADCs enter recurrent uterine cancer.

Ayal Aizer, MD, MHS, explains how expanded trial data have broadened eligibility for stereotactic radiosurgery in patients with brain metastases, including higher tumor counts.

In a SEER-based cohort of more than 20,000 adults, 5-year Hodgkin lymphoma survivors had nearly double the all-cause mortality of the general population.

The European Commission based its approval of teclistamab plus daratumumab for relapsed/refractory multiple myeloma on data from the MajesTEC-3 study.

The FDA accepted a priority review application for dostarlimab in untreated dMMR/MSI-H locally advanced rectal cancer, backed by AZUR-1 trial data.

Sunil Singhal, MD, discussed how fluorescence imaging via abenacianine helps surgeons visualize tumors missed during lung cancer surgery.

Frank McCormick, PhD, FRS, DSc (Hon), spoke about how targeting KRAS may eventually lead to the prevention of pancreatic cancer.

Lizza Hendriks, MD, PhD, discussed why excluding patients with brain metastases from clinical trials is no longer ethical.

Sunil Singhal, MD, explained how a fluorescent dye technology helps surgeons see and remove tumors more completely.

The platinum-free interval is prognostic but not predictive for lenvatinib plus pembrolizumab, Susana Campos, MD, MPH, told CancerNetwork.

Experts compared outcomes for NALIRIFOX in patients with metastatic pancreatic cancer based on real-world and clinical trial data.

Five-year follow-up showed 37% overall survival rate with lenvatinib plus pembrolizumab in dMMR endometrial cancer.

Up to 55% of endometrial tumors show HER2/neu heterogeneity, explained Susana Campos, MD, MPH, making biopsy at recurrence key for ADC eligibility.

The next major problem to tackle for SRS in brain metastases management is how to handle necrosis rates, according to Ayal Aizer, MD, MHS.